CRIS Current Research Information System

PECCI, FEDERICA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 102
NA - Nord America 82
EU - Europa 28
Totale 212
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 82
SG - Singapore 56
CN - Cina 27
IT - Italia 17
IN - India 10
ID - Indonesia 6
IL - Israele 3
NL - Olanda 3
BG - Bulgaria 2
FR - Francia 2
BE - Belgio 1
DE - Germania 1
FI - Finlandia 1
GR - Grecia 1
Totale 212
Salva come PNG Salva come JPEG
Città #
Singapore 50
Santa Clara 42
Boardman 16
Hyderabad 7
Jakarta 6
Bologna 4
Verona 4
Pietrasanta 3
Tel Aviv 3
Ashburn 2
Foshan 2
Guangzhou 2
Harbin 2
Milan 2
New Delhi 2
Shanghai 2
Sofia 2
Wuxi 2
Arezzo 1
Dongguan 1
Falkenstein 1
Helsinki 1
Jiangmen 1
Kunming 1
Luohe 1
Mechelen 1
Thessaloniki 1
Velletri 1
Weifang 1
Wenzhou 1
Wuhan 1
Zhengzhou 1
Totale 167
Salva come PNG Salva come JPEG
Nome #
Dissecting the clinicopathologic, genomic, and immunophenotypic correlates of KRASG12D-mutated non-small-cell lung cancer 25
Resistance to KRAS G12C Inhibition in Non-small Cell Lung Cancer 25
Erratum to ‘Evaluation of COVID-19 impact on DELAYing diagnostic-therapeutic pathways of lung cancer patients in Italy (COVID-DELAY study): fewer cases and higher stages from a real-world scenario’: [ESMO Open Volume 7, Issue 2, April 2022, 100406] 22
A multicentre study of pembrolizumab time-of-day infusion patterns and clinical outcomes in non-small-cell lung cancer: too soon to promote morning infusions 21
Impact of TMB/PD-L1 expression and pneumonitis on chemoradiation and durvalumab response in stage III NSCLC 18
Clonal KEAP1 mutations with loss of heterozygosity share reduced immunotherapy efficacy and low immune cell infiltration in lung adenocarcinoma 17
Non-small-cell lung cancer: how to manage EGFR-mutated disease 17
Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors 15
Genomic and Immunophenotypic Landscape of Acquired Resistance to PD-(L)1 Blockade in Non-Small-Cell Lung Cancer 15
How to manage KRAS G12C-mutated advanced non-small-cell lung cancer 14
Advanced non-small-cell lung cancer: how to manage EGFR and HER2 exon 20 insertion mutation-positive disease 12
Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer 11
Efficacy of PD-(L)1 blockade monotherapy compared with PD-(L)1 blockade plus chemotherapy in first-line PD-L1-positive advanced lung adenocarcinomas: A cohort study 9
Impact of Aneuploidy and Chromosome 9p Loss on Tumor Immune Microenvironment and Immune Checkpoint Inhibitor Efficacy in NSCLC 9
Title: Clinicopathologic, genomic, and immunophenotypic landscape of ATM mutations in non-small cell lung cancer 8
Clinicopathologic and Genomic Factors Impacting Efficacy of First-Line Chemoimmunotherapy in Advanced NSCLC 7
Totale 245
Salva come PNG Salva come JPEG
Categoria #
all - tutte 1.043
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 1.043
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2022/20236 0 0 0 0 0 0 0 0 2 2 0 2
2023/202434 0 1 1 2 1 2 2 13 2 4 1 5
2024/2025205 5 42 59 27 72 0 0 0 0 0 0 0
Totale 245